期刊文献+

鼻咽癌患者外周血IL-10的测定和分析 被引量:2

暂未订购
导出
摘要 目的探讨鼻咽癌患者治疗前外周血IL-10的水平与临床分期等因素的关系,寻找与鼻咽癌临床分期相关的生物学指标,并为鼻咽癌的免疫治疗提供科学依据。方法采用流式细胞微球阵列(CBA)检测符合入选标准的152例鼻咽癌患者治疗前外周血的IL-10水平,对不同性别、年龄、病理、EB病毒滴度、临床分期分组的IL-10水平进行比较。结果男性患者的IL-10水平低于女性患者;低年龄组患者的IL-10水平低于高年龄组患者;病理为分化型非角化性癌的患者的IL-10水平高于未分化型非角化性癌的患者;低VCA-IgA滴度的鼻咽癌患者的IL-10水平高于高VCA-IgA滴度的鼻咽癌患者;低EA-IgA滴度的鼻咽癌患者的IL-10水平高于高EA-IgA滴度的患者;低DNA酶中和率滴度的鼻咽癌患者的IL-10水平高于高DNA酶中和率滴度的患者;低N分期的鼻咽癌患者的IL-10水平低于高N分期患者;低临床分期的鼻咽癌患者的IL-10水平低于高临床分期患者,但差异均无显著性(P>0.05)。低T分期的鼻咽癌患者的IL-10水平低于高T分期患者,差异有显著性(P<0.05)。结论随着T分期的提高,IL-10水平也升高,IL-10可作为鼻咽癌T分期的生物学指标。
出处 《广东医学》 CAS CSCD 北大核心 2009年第6期930-931,共2页 Guangdong Medical Journal
  • 相关文献

参考文献8

  • 1周文,吴平,谭继全.鼻咽癌患者外周血Th1/Th2细胞因子的变化趋势及其临床意义[J].中国中西医结合耳鼻咽喉科杂志,2006,14(4):212-214. 被引量:1
  • 2张康,钟运超,郭胜春,张振胜,陈永雄,莫洁庭,钱水英.鼻咽癌患者外周血IFN-γ和IL-10检测与临床分期的关系[J].广西医学,2004,26(11):1687-1688. 被引量:2
  • 3SPITS H,DE WAAL MALEFYT R.Functional characterization of human IL-10[J].Int Arch Allergy Immunol,1992,99(1):8-15.
  • 4DE WAAL MALEFYT R,ABRAMS J,BENNETT B,et al.Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes:an autoregulatory role of IL-10 produced by monocytes[J].J Exp Med,1991,174(5):1 209-1 220.
  • 5YANG L,CARBONE D P.Tumor-host immune interactions and dendritic cell dysfunction[J].Adv Cancer Res,2004,92:13-27.
  • 6GROUX H,BIGLER M,DE VRIES J E,et al.Inhibitory and stimulatory effects of IL-10 on human CD8+T cells[J].J Immunol,1998,160(7):3 188-3 193.
  • 7MOORE K W,DE WAAL MALEFYT R,COFFMAN R L,et al.Interleukin-10 and the interleukin-10 receptor[J].Annu Rev Immunol,2001,19:683-765.
  • 8FUJIEDA S,LEE K,SUNAGA H,et al.Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma[J].Cancer,1999,85(7):1 439-1 445.

二级参考文献9

共引文献1

同被引文献28

  • 1高小青,谢艳华.胃癌患者血清IL-6、IL-8及IL-10的表达及意义[J].山东医药,2008,48(5):75-76. 被引量:9
  • 2WittkeF, HoffmannR, BuerJ, eta1. Interleukinl0: anim- munosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. British Journal of Cancer, 1999, 79 (8): 1182-1184.
  • 3Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual, 7thed [M]. New York: Springer, 2010: 4-6.
  • 4Yue FY, Dummer R, Geertsen R, et al. Interleukin 10 is agrowth factor for human melanoma cells and downregulates HLA clss- I, HLA clss-lland ICAM-1 molecules [J]. Int J Cancer, 1997, 71 (4): 630-637.
  • 5JtmeCH, BluestoneJA, NadlerLM, etM. TheB7andCD28 receptor families [J]. ImmunolToday, 1994, 15 (7): 321-331.
  • 6Chang CK, Zdon MJ. Inhibition of tumor necrosis factor-alpha and inducible nitric oxide synthase correlates with the induction of IL-10 in septic rats undergoing laparotomy and laparoscopy [J]. Surg Laparose Endosc Percutan Tech, 2002, 12 (4): 247-251.
  • 7Groux H, Bigler M, De Vries JE, et al. Inhibitory and stimulatory effects of IL-10 on human CDS+ T cells [J]. J Im- munol, 1998, 160 (7): 3188-3193.
  • 8Petersson M, Charo J, Salazar-Onfray F, et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP) -1/2 function in the prototype NK target YAC-1 [J]. J Immunol, 1998, 161 (5): 2099-2105.
  • 9Fujieda S, Saito H, Hoshino T. Responses to killer cells in head and neck cancer patients [J]. Eur Arch. Otorhinolaryngol, 1990, 247 (3): 176-181.
  • 10Young MR, Wright MA, Lozano Y, et al. Mechanisms of immune suppression in patients with head and neck cancer: in- fluence on the immune infiltrate of cancer [J]. Int. J. Cancer, 1996, 67 (3): 333-338.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部